Enric C. C.
- Country
- Spain
- Department
- Oncology
Research Overview
- Evaluation of Debio 0123 Combined with Carboplatin and Etoposide in Adults with Recurrent or Progressive Small Cell Lung Cancer Post-Platinum Therapy
- Evaluation of MEDI5752 in Patients with Advanced Solid Tumors: A Clinical Trial
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Data & Insights
Has run more than one trial at 467 of 811 partner sites.
Specializations
Lung Cancer Expertise
Specializes in treating various forms of non-small cell lung cancer (NSCLC), with particular emphasis on advanced and metastatic disease states. Works extensively with targeted therapies for patients with specific genetic mutations, including EGFR, ALK, and HER2 alterations.
- Advanced NSCLC Treatment
- Small Cell Lung Cancer (SCLC)
- Targeted Molecular Therapies
Immunotherapy Applications
Focuses on novel immunotherapy combinations for cancer treatment, particularly involving checkpoint inhibitors. Investigates innovative approaches combining immunotherapy with conventional treatments for enhanced therapeutic outcomes.
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy
- Novel Therapeutic Approaches
Hematologic Malignancies
Conducts research in various blood cancers, including chronic myeloid leukemia, myelofibrosis, and related disorders. Explores innovative treatment approaches for hematologic conditions with a focus on targeted therapies.
- Blood Cancer Treatment
- Myeloproliferative Disorders
- Novel Therapeutic Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.